For example, we previously reported that the phosphorylation state of HER3 could discriminate those patients with HER2+ inflammatory breast cancers who were more likely to respond to lapatinib monotherapy [16]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.